AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38956562 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional video followed by self-study (Vid-Self) in Study 2 (n=30)
Number of subjects: 138
Study 38956562 — intervention group
Group type: COMPARATOR
Intervention: Self-study followed by instructional video (Self-Vid) in Study 2 (n=30)
Number of subjects: 138
Study 38956594 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg psilocybin
Number of subjects: 50
Study 38956594 — intervention group
Group type: COMPARATOR
Intervention: 25 mg microcrystalline cellulose (MCC) placebo
Number of subjects: 50
Study 38956594 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin and MCC placebo
Number of subjects: 50
Study 38956609 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail-order pharmacy dispensing for medication abortion
Number of subjects: 24
Study 38956628 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial support delivered by traditional healers for 12 months
Number of subjects: 650
Study 38956628 — intervention group
Group type: COMPARATOR
Intervention: Standard clinic-based HIV care alone
Number of subjects: 650
Study 38956637 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention bundle
Number of subjects: 16
Study 38956637 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 16
Study 38956664 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine combined with dexmedetomidine
Number of subjects: 134
Study 38956664 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine alone
Number of subjects: 134
Study 38956675 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention group (Heart4U application)
Number of subjects: 580
Study 38956675 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 580
Study 38956676 — intervention group
Group type: EXPERIMENTAL
Intervention: INtubate-RECruit-SURfactant-Extubate (IN-REC-SUR-E)
Number of subjects: 382
Study 38956676 — intervention group
Group type: COMPARATOR
Intervention: Less-invasive surfactant administration (LISA)
Number of subjects: 382
Study 38956698 — intervention group
Group type: EXPERIMENTAL
Intervention: D3 lymph node dissection
Number of subjects: 0
Study 38956698 — intervention group
Group type: COMPARATOR
Intervention: D2 lymph node dissection
Number of subjects: 0
Study 38956809 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine exposure with a 20% dose increase for low exposure
Number of subjects: 15
Study 38956809 — intervention group
Group type: COMPARATOR
Intervention: Vincristine exposure without dose increase
Number of subjects: 15
Study 38956881 — intervention group
Group type: COMPARATOR
Intervention: Supportive periodontal care with subgingival instrumentation (control)
Number of subjects: 62
Study 38956881 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive periodontal care without subgingival instrumentation (test)
Number of subjects: 62
Study 38956881 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SPC with and without instrumentation)
Number of subjects: 62
Study 38956935 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA)
Number of subjects: 0
Study 38956940 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided strategy
Number of subjects: 551
Study 38956940 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided strategy
Number of subjects: 551
Study 38956940 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided PCI
Number of subjects: 551
Study 38956940 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI
Number of subjects: 551
Study 38956940 — intervention group
Group type: COMPARATOR
Intervention: Negative FFR
Number of subjects: 551
Study 38956940 — intervention group
Group type: COMPARATOR
Intervention: Negative IVUS
Number of subjects: 551
Study 38957011 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy sampling during EGD
Number of subjects: 671
Study 38957026 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38957149 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD and BPD symptoms
Number of subjects: 0
Study 38957151 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 250
Study 38957201 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 as an adjuvant therapy to letrozole
Number of subjects: 0
Study 38957201 — intervention group
Group type: COMPARATOR
Intervention: Letrozole alone (control)
Number of subjects: 0
Study 38957349 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (rESWT) with 3 sessions at 2000 impulses, 2.2 Bars pressure, 8 Hz frequency, with a 2-week interval between sessions (Experimental Group A)
Number of subjects: 72
Study 38957349 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (rESWT) with 3 sessions at 2000 impulses, 2.2 Bars pressure, 8 Hz frequency, with a 4-week interval between sessions (Experimental Group B)
Number of subjects: 72
Study 38957349 — intervention group
Group type: COMPARATOR
Intervention: Control Group receiving 3 rESWT sessions with a 1-week interval between each session
Number of subjects: 72
Study 38957588 — intervention group
Group type: EXPERIMENTAL
Intervention: A2 milk
Number of subjects: 40
Study 38957588 — intervention group
Group type: COMPARATOR
Intervention: A1/A2 milk
Number of subjects: 40
Study 38957727 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-life basic education
Number of subjects: 108
Study 38957856 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app-based mindfulness intervention
Number of subjects: 56
Study 38957856 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 56
Study 38957926 — intervention group
Group type: EXPERIMENTAL
Intervention: Gyrolab for quantifying CB307
Number of subjects: 0
Study 38958059 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (children with large overjet due to mandibular retrognathia)
Number of subjects: 37
Study 38958059 — intervention group
Group type: COMPARATOR
Intervention: Control group (children with neutral occlusion)
Number of subjects: 37
Study 38958149 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 9132
Study 38958195 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin 11.25 mg at baseline (≤ 8 weeks after RP) and at 3 and 6 months
Number of subjects: 226
Study 38958195 — intervention group
Group type: COMPARATOR
Intervention: Active surveillance
Number of subjects: 226
Study 38958195 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin
Number of subjects: 226
Study 38958479 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag plus diacerein
Number of subjects: 102
Study 38958479 — intervention group
Group type: COMPARATOR
Intervention: Eltrombopag monotherapy
Number of subjects: 102
Study 38958732 — intervention group
Group type: EXPERIMENTAL
Intervention: Centanafadine
Number of subjects: 0
Study 38958732 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate hydrochloride ER (Concerta)
Number of subjects: 0
Study 38958839 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid eGFR decline
Number of subjects: 804237
Study 38958839 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean annual eGFR decline
Number of subjects: 804237
Study 38958845 — intervention group
Group type: EXPERIMENTAL
Intervention: New line of therapy following osimertinib and PBC
Number of subjects: 273
Study 38958845 — intervention group
Group type: EXPERIMENTAL
Intervention: New line of therapy following osimertinib and PBC (matched subset)
Number of subjects: 273
Study 38958846 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib plus abiraterone acetate and prednisone (AAP)
Number of subjects: 0
Study 38958846 — intervention group
Group type: COMPARATOR
Intervention: Olaparib monotherapy
Number of subjects: 0
Study 38958846 — intervention group
Group type: COMPARATOR
Intervention: Olaparib plus AAP
Number of subjects: 0
Study 38958846 — intervention group
Group type: COMPARATOR
Intervention: Talazoparib plus enzalutamide
Number of subjects: 0
Study 38958913 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily
Number of subjects: 6355
Study 38958913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6355
Study 38958913 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 6355
Study 38958978 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral self-help intervention (12 weekly modules)
Number of subjects: 154
Study 38958978 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (routine care only)
Number of subjects: 154
Study 38958989 — intervention group
Group type: EXPERIMENTAL
Intervention: Lerodalcibep, 300 mg, subcutaneous injection, monthly for 52 weeks
Number of subjects: 922
Study 38958989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 922
Study 38959017 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 78
Study 38959017 — intervention group
Group type: COMPARATOR
Intervention: Very low-energy diet (VLED)
Number of subjects: 78
Study 38959024 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided 8-week web-based intervention
Number of subjects: 1607
Study 38959264 — intervention group
Group type: EXPERIMENTAL
Intervention: Water service quality improvements
Number of subjects: 0
Study 38959264 — intervention group
Group type: EXPERIMENTAL
Intervention: Water quantity supplied
Number of subjects: 0
Study 38959264 — intervention group
Group type: EXPERIMENTAL
Intervention: Water service continuity
Number of subjects: 0
Study 38959264 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased water supply by 5 L/user/day
Number of subjects: 0
Study 38959264 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased water supply by 1.2 hours per day
Number of subjects: 0
Study 38959294 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally-enabled community health worker (CHW) care (digital platform + CHW)
Number of subjects: 56
Study 38959294 — intervention group
Group type: COMPARATOR
Intervention: CHW-enhanced usual care (CHW only)
Number of subjects: 56
Study 38959480 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisotumab vedotin (2.0 mg/kg every 3 weeks)
Number of subjects: 502
Study 38959480 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (investigator's choice: topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed)
Number of subjects: 502
Study 38959480 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (investigator's choice)
Number of subjects: 502
Study 38959500 — intervention group
Group type: EXPERIMENTAL
Intervention: QCG-Critical score for critical events (AI-based ECG score)
Number of subjects: 1254
Study 38959500 — intervention group
Group type: EXPERIMENTAL
Intervention: QCG-Critical score (AI-based ECG score)
Number of subjects: 1254
Study 38959589 — intervention group
Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 149
Study 38959589 — intervention group
Group type: COMPARATOR
Intervention: Female patients
Number of subjects: 149
Study 38959779 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod (15 mg twice daily for 52 weeks)
Number of subjects: 14
Study 38960001 — intervention group
Group type: EXPERIMENTAL
Intervention: STH≤2 mm (A-I)
Number of subjects: 80
Study 38960001 — intervention group
Group type: EXPERIMENTAL
Intervention: STH>2 mm (B-I)
Number of subjects: 80
Study 38960001 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcrestal placement (A-II, B-II)
Number of subjects: 80
Study 38960001 — intervention group
Group type: EXPERIMENTAL
Intervention: STH>2 mm
Number of subjects: 80
Study 38960044 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg plus ramipril for 4 weeks
Number of subjects: 79
Study 38960044 — intervention group
Group type: COMPARATOR
Intervention: Hyperglycemia
Number of subjects: 79
Study 38960044 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 79
Study 38960463 — intervention group
Group type: EXPERIMENTAL
Intervention: Active MRI-guided rTMS
Number of subjects: 48
Study 38960463 — intervention group
Group type: COMPARATOR
Intervention: Sham MRI-guided rTMS
Number of subjects: 48
Study 38960464 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmentectomy
Number of subjects: 307
Study 38960465 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A: Rapid hepatitis C virus (HCV) antibody testing
Number of subjects: 0
Study 38960465 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B: Rapid HCV antibody and rapid RNA testing
Number of subjects: 0
Study 38960465 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm C: Rapid HCV antibody testing and same-day treatment initiation for HCV antibody-positive participants
Number of subjects: 0
Study 38960465 — intervention group
Group type: COMPARATOR
Intervention: Control arm: Standard of care
Number of subjects: 0
Study 38960495 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network intervention (weekly social-health classroom interventions for 9 to 10 months)
Number of subjects: 494
Study 38960495 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 494
Study 38960508 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid
Number of subjects: 13970
Study 38960508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13970
Study 38960570 — intervention group
Group type: COMPARATOR
Intervention: Control group following Mediterranean diet recommendations
Number of subjects: 193
Study 38960570 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Nutrition (PN)
Number of subjects: 193
Study 38960570 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Plan (PP)
Number of subjects: 193
Study 38960570 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized recommendations (PN and PP)
Number of subjects: 193
Study 38960586 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion Body Myositis Functional Rating Scale (IBMFRS)
Number of subjects: 150
Study 38960600 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative ACP (col-ACP)
Number of subjects: 277
Study 38960600 — intervention group
Group type: COMPARATOR
Intervention: Supportive intervention (active control)
Number of subjects: 277
Study 38960600 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 277
Study 38960626 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (30% symptom improvement at 2 months)
Number of subjects: 60
Study 38960626 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD treatment responders
Number of subjects: 60
Study 38960626 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD nonresponders
Number of subjects: 60
Study 38960626 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 60
Study 38960798 — intervention group
Group type: EXPERIMENTAL
Intervention: durvalumab + olaparib
Number of subjects: 50
Study 38960798 — intervention group
Group type: EXPERIMENTAL
Intervention: durvalumab + cediranib
Number of subjects: 50
Study 38960798 — intervention group
Group type: EXPERIMENTAL
Intervention: durvalumab + olaparib and durvalumab + cediranib
Number of subjects: 50
Study 38960812 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 19000
Study 38960812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19000
Study 38960832 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine (2.5, 5.0, or 7.5 mg) administered twice daily from the morning of surgery until postoperative day 2.
Number of subjects: 78
Study 38960832 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered twice daily from the morning of surgery until postoperative day 2.
Number of subjects: 78
Study 38960881 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted oesophagectomy (RAO)
Number of subjects: 203
Study 38960881 — intervention group
Group type: COMPARATOR
Intervention: Video-assisted thoracoscopic oesophagectomy (VAO)
Number of subjects: 203
Study 38960885 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 442
Study 38960885 — intervention group
Group type: COMPARATOR
Intervention: Totally laparoscopic distal gastrectomy (TLDG)
Number of subjects: 442
Study 38960907 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for 48 weeks
Number of subjects: 14
Study 38960907 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 48 weeks
Number of subjects: 14
Study 38960969 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer levels
Number of subjects: 572
Study 38960969 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-proADM levels
Number of subjects: 572
Study 38960969 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin levels
Number of subjects: 572
Study 38960969 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 572
Study 38960969 — intervention group
Group type: EXPERIMENTAL
Intervention: ADL index
Number of subjects: 572
Study 38961047 — intervention group
Group type: EXPERIMENTAL
Intervention: mAb treatment (casirivimab plus imdevimab 1200 mg)
Number of subjects: 2077
Study 38961193 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led sexual rehabilitation intervention
Number of subjects: 229
Study 38961193 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 229
Study 38961385 — intervention group
Group type: EXPERIMENTAL
Intervention: First mobilization out of bed within the first 24 hours after surgery
Number of subjects: 290
Study 38961385 — intervention group
Group type: EXPERIMENTAL
Intervention: First mobilization within 6 hours after surgery
Number of subjects: 290
Study 38961385 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to first mobilization after surgery
Number of subjects: 290
Study 38961385 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of first mobilization session
Number of subjects: 290
Study 38961385 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between intubation time and first mobilization timing
Number of subjects: 290
Study 38961385 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between timing of mobilization and duration of mobilization session
Number of subjects: 290
Study 38961388 — intervention group
Group type: EXPERIMENTAL
Intervention: MiECC
Number of subjects: 60
Study 38961388 — intervention group
Group type: COMPARATOR
Intervention: CECC
Number of subjects: 60
Study 38961397 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 63
Study 38961397 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 63
Study 38961419 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of biomarkers including I-FABP, Alpha-GST, IL-6, PCT, IMA, D-lactate, D-dimer, SCUBE-1, LBP
Number of subjects: 250
Study 38961419 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers with at least moderate accuracy
Number of subjects: 250
Study 38961419 — intervention group
Group type: EXPERIMENTAL
Intervention: Best models for each comparison
Number of subjects: 250
Study 38961421 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle-only group
Number of subjects: 0
Study 38961421 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle + medical food group
Number of subjects: 0
Study 38961421 — intervention group
Group type: COMPARATOR
Intervention: Combined intervention groups
Number of subjects: 0
Study 38961421 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 38961430 — intervention group
Group type: EXPERIMENTAL
Intervention: LVL UP App (holistic lifestyle intervention)
Number of subjects: 0
Study 38961430 — intervention group
Group type: EXPERIMENTAL
Intervention: Oura ring (for tracking physical activity, sleep, and heart rate variability)
Number of subjects: 0
Study 38961430 — intervention group
Group type: EXPERIMENTAL
Intervention: HAPPY App (provides health promotion information)
Number of subjects: 0
Study 38961430 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic lifestyle mHealth intervention
Number of subjects: 0
Study 38961430 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy and psychoeducational coaching sessions, daily 'Life Hacks', slow-paced breathing exercises, step tracker, low-burden food diary, journaling tool
Number of subjects: 0
Study 38961430 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (not specified)
Number of subjects: 0
Study 38961439 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront cytoreductive nephrectomy (CN)
Number of subjects: 55
Study 38961439 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred cytoreductive nephrectomy (CN)
Number of subjects: 55
Study 38961439 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy (ST) only with nivolumab plus ipilimumab
Number of subjects: 55
Study 38961443 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin transfusion thresholds
Number of subjects: 0
Study 38961460 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal therapeutic intervention with additional photobiomodulation therapy (PBMT)
Number of subjects: 0
Study 38961460 — intervention group
Group type: COMPARATOR
Intervention: Stand-alone multimodal therapeutic intervention
Number of subjects: 0
Study 38961462 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-symbolic magnitude comparison task
Number of subjects: 15
Study 38961462 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory index
Number of subjects: 15
Study 38961468 — intervention group
Group type: EXPERIMENTAL
Intervention: INTELLiVENT-adaptive support ventilation (ASV)
Number of subjects: 328
Study 38961468 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 328
Study 38961468 — intervention group
Group type: EXPERIMENTAL
Intervention: INTELLiVENT-ASV
Number of subjects: 328
Study 38961489 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (staff-led physical activity intervention)
Number of subjects: 819
Study 38961489 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 819
Study 38961496 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional and multiprofessional care assessment through a cross-sectional survey
Number of subjects: 500
Study 38961501 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive machine-learning algorithm to prompt interpreter services
Number of subjects: 35